NervGen Pharma Corp. , a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced positive topline results from the chronic cohort (1-10 years post injury) ...

UT Southwestern Medical Center scientists have identified a protein that appears to act as a master control switch for ...

An evolutionarily conserved mechanism for cAMP elicited axonal regeneration involves direct activation of the dual leucine zipper kinase DLK. Elife. 2016 Jun 7;5PubMed PMID: 27268300. Xiong X, Hao Y, ...

Spinal cord injury (SCI) is a devastating, debilitating, and life-altering condition that currently lacks a definitive cure or highly effective treatment ...

NurExone expects to initiate a Phase 1/2a clinical trial in 2026 (" 2026 SCI Trial ”) marking a major milestone in the advancement of regenerative therapies for central nervous system injuries.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...

After injury, regeneration of retinal ganglion cells and reconnection to their original target — the suprachiasmatic nucleus —is achieved by manipulating guidance cues, leading to the ...